NASDAQ$RVMD
REVOLUTION Medicines Inc · Q3 2025 earnings
Q3 2025 earnings · · After market close · Investor relations
Briefing
Revolution Medicines reported Q3 2025, a net loss of $305.2M.
For Q3 2025, Revolution Medicines reported a net loss of $305.2M. Management discussed operating trends, liquidity, and priorities as disclosed in the quarterly filing.
- Net loss $305.2M.
- Revolution Medicines updated strategic and capital priorities in the filing.
- Revolution Medicines updated strategic and capital priorities in the filing.
Headline financials
Revenue & EPS history
Revolution Medicines · Revenue · Quarterly
$629K
Forward guidance
The filing discusses Revolution Medicines's outlook, capital deployment, and key risks without relying solely on numeric EPS guidance.
Tailwinds
- Revolution Medicines cited execution on strategic priorities in the filing.
- Balance sheet and liquidity support continued operations.
- Pipeline milestones remain the primary value driver.
Headwinds
- GAAP profitability remained under pressure in the quarter.
- Macro, competitive, and cost pressures may affect margins.
- Segment mix and one-time items can affect comparability.
- Clinical-stage spend continues ahead of commercial revenue.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2025
+0.1%
Avg return
Earnings day
+0.2%
Avg return
5 days after
+6.7%
Avg return
30 days after
42%
11 / 26 earnings
Positive
+11.7%
Q3 2020
Best reaction
-11.7%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.6% | -2.1% | +1.4% | |
| Q4 2025 | -0.9% | -2.7% | -10.4% | |
| Q3 2025 | +3.5% | +8.0% | +34.2% | |
| Q2 2025 | -4.7% | -3.8% | +10.4% | |
| Q1 2025 | +11.4% | +6.1% | +9.1% | |
| Q4 2024 | -3.5% | -6.3% | -7.8% | |
| Q3 2024 | +4.1% | +6.8% | -15.3% | |
| Q2 2024 | -3.0% | -0.7% | -3.3% | |
| Q1 2024 | -3.7% | -4.4% | +3.8% | |
| Q4 2023 | +3.0% | +0.2% | +6.7% | |
| Q3 2023 | -3.0% | -11.1% | +8.2% | |
| Q2 2023 | -0.1% | +1.2% | +8.3% | |
| Q1 2023 | +3.5% | +6.3% | +10.6% | |
| Q4 2022 | +10.0% | +4.6% | -11.5% | |
| Q3 2022 | -4.1% | +8.1% | +17.8% | |
| Q2 2022 | +0.5% | +4.2% | -11.1% | |
| Q1 2022 | -6.4% | -7.8% | +15.4% | |
| Q4 2021 | -6.4% | -12.7% | +29.1% | |
| Q3 2021 | -1.7% | -2.5% | -24.4% | |
| Q2 2021 | -11.7% | -5.6% | +9.7% | |
| Q1 2021 | +7.1% | +8.2% | +10.7% | |
| Q4 2020 | -9.2% | -1.1% | +1.8% | |
| Q3 2020 | +11.7% | +10.7% | +17.4% | |
| Q2 2020 | +6.9% | -3.8% | +8.3% | |
| Q1 2020 | -1.3% | +0.8% | +4.9% | |
| Q4 2019 | -2.5% | +4.2% | +49.6% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro